| ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation (PR Newswire) eResearchTechnology, Inc. , , a global provider of technology and services to the pharmaceutical, biotechnology, and medical device industries, announced the successful closing of the acquisition of the Research Services Division of CareFusion Corporation . Â CRS is a leading provider of respiratory diagnostics services and manufacturer of diagnostic devices and also offers cardiac safety and ePRO services. Â The combined company offers a market leading position in the very attractive clinical research market for cardiac safety services, cardiac safety consulting, respiratory services, ePRO services, and medical devices. Â The acquisition will serve to diversify ERT's revenue base, expand its global footprint, and increase the potential for development of new services and products in clinical research and healthcare delivery. us.rd.yahoo.com |
Nature Made® GreatMind - Video NATURE MADE GreatMind Brain Game Challenge Launched To Educate Adults About Cognitive Health feedproxy.google.com |
Medtronic to Buy Osteotech for $123 Million Medtronic said it will buy Osteotech for about $123 million. Osteotech, a provider of human bone and bone connective tissue used in transplants, has been embroiled in a proxy battle. online.wsj.com |
Are RNAi Leaders About to Be Snatched Up by Big Pharma? M.E. Garza submits: Shares of RXi Pharmaceuticals Corporation (RXII) closed Thursday at $2.30+0.21 (up 10.05%) and reached as high as $2.45 after noted the loud and credible chatter we're hearing involving a substantial deal with one of the the world’s largest drugmakers. According to our sources, this recognized leader in RNAi-based therapeutic discovery and development is close to announcing that they have reached an agreement with the pharmaceutical company which "has been pushing hard to get into the RNAi space."The pharmaceutical industry has seen some $230 billion in M&A activity from the top 10 pharmaceutical companies alone since the beginning of 2007, but as we reported just days ago, the largest drug makers are likely to continue making acquisitions and signing pricey partnership deals after struggling to develop new "hit drugs" of their own.Complete Story » seekingalpha.com |
Glaxo to Build New Plant in U.K. GlaxoSmithKline said it will build its first new manufacturing capacity in Britain in about 25 years in response to the U.K. government's plan to cut the rate of corporation tax on income from patents. online.wsj.com |